title: Clinical and biochemical correlates of starting "daily" hemodialysis.
abstract: BACKGROUND
  Daily hemodialysis has been proposed to improve outcomes for patients with end-stage renal disease. There has been increasing evidence that daily hemodialysis might have potential advantages over intermittent dialysis. However, despite these potential advantages, daily hemodialysis is infrequently used in the United States, and published accounts on the technique are few.
  
  
  METHODS
  We describe patient outcomes after increasing their hemodialysis frequency from three to six times per week in a cohort of 72 patients treated at nine centers during 1972 to 1996. Analyses of predialysis blood pressure and laboratory parameters from 6 months before until 12 months after starting frequent hemodialysis used a repeated-measures statistical technique.
  
  
  RESULTS
  Predialysis systolic and diastolic blood pressures fell by 7 and 4 mm Hg, respectively, after starting frequent hemodialysis (P = 0.02). Reductions were greatest among patients being treated with antihypertensive medications, despite a reduction in their dosage of medications. Postdialysis weight fell by 1.0% within one month of starting frequent hemodialysis and improved control of hypertension. After the initial drop, postdialysis weight increased at a rate of 0.85 kg per six months. Serum albumin rose by 0.29 g/dl (P < 0.001) between months 1 to 12 of treatment with daily hemodialysis. Hematocrit rose by 3.0 percentage points (P = 0.02) among patients (N = 56) not treated with erythropoietin during this period. Two years after the start of daily hemodialysis, Kaplan-Meier analyses showed a patient survival of 93%, a technique survival of 77%, and an arteriovenous fistula patency of 92%. Vascular access patency was excellent despite more frequent use of the access.
  
  
  CONCLUSIONS
  These results suggest that in certain patients, daily hemodialysis might have advantages over three times per week hemodialysis.
authors.affiliation: University Renal Research and Educational Association, Department of Medicine, University of Michigan, Ann Arbor, USA.
authors.forename: J D
authors.initials: JD
authors.lastname: Woods
authors.forename: F K
authors.initials: FK
authors.lastname: Port
authors.forename: S
authors.initials: S
authors.lastname: Orzol
authors.forename: U
authors.initials: U
authors.lastname: Buoncristiani
authors.forename: E
authors.initials: E
authors.lastname: Young
authors.forename: R A
authors.initials: RA
authors.lastname: Wolfe
authors.forename: P J
authors.initials: PJ
authors.lastname: Held
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects; D001794:Blood Pressure; D001835:Body Weight; D002130:Calcium Phosphates / Q000097:blood; D002784:Cholesterol / Q000097:blood; D015331:Cohort Studies; D005060:Europe; D005260:Female; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000379:methods*; D012709:Serum Albumin / Q000378:metabolism; D013997:Time Factors; D014481:United States
chemical_list: D002130:Calcium Phosphates; D012709:Serum Albumin; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; C485838:calcium phosphate, monobasic, anhydrous; D002784:Cholesterol; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous